Challenges of effective safety messaging in the healthcare ... · DOTAREM GUE GADOVIST MAGNEVIST...
Transcript of Challenges of effective safety messaging in the healthcare ... · DOTAREM GUE GADOVIST MAGNEVIST...
Challenges of effective safety messaging in the healthcare systemDr June RaineDirector, Vigilance and Risk Management of Medicines
2
In this talk
Why need to strengthen safety messaging?
What are current challenges?
How move forward? Some examples
Where next - current opportunities?
3
What is the MHRA’s role?
Availability of new treatments and technologies
Proactive vigilance and prompt risk management
Prompt information to healthcare professionals and patients on benefit risk change
Monitoring effectiveness of risk minimisation
4
Why need for effective safety messaging?
Pirmohamed et al 2004 BMJ 329; 15-19
6.5% hospital admissions in UK relate to adverse drug reactionsADRs were responsible for death in 0.15%72% were classified as avoidable
5
Today’s multiple safety messaging tools
6
“Messages on safety are being compromised by the number of NHS central bodies and watchdogs issuing advice”
Sir Bruce Keogh 2017
Challenges for healthcare systems
7
Range of potential target audiences
8
Changing healthcare context
9
HRT and increased risk of breast cancer
Monitoring outcomes of safety messaging
10
Systems thinking
EducationImpact & outcomes
Today’s four safety messaging themes
Digital solutions
11
Metal on Metal hip
NSAIDs-diclofenac
Gadolinium contrast agents
Four safety messaging examples
Sodium valproate
12
Metal on metal hip replacements –soft tissue reactions
13
Gadolinium contrast agents - risk of NSF Gadolinium-containing agents
UK Usage 2006 - 2010
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
Q12006
Q22006
Q32006
Q42006
Q12007
Q22007
Q32007
Q42007
Q12008
Q22008
Q32008
Q42008
Q12009
Q22009
Q32009
Q42009
Q12010
Q22010
Q32010
Q42010
Q12011
Quarter
Vial
s di
spen
sed
DOTAREM GUE GADOVIST MAGNEVIST PROHANCE MULTIHANCE PRIMOVIST OMNISCAN VASOVIST
MHRA Drug Safety Update
14
NSAIDs and cardiovascular risk
Prescribing of NSAIDs
Hollingsbee et al 2011
15
0
10
20
30
40
50
60
Dec‐05
Mar‐06
Jun‐06
Sep‐06
Dec‐06
Mar‐07
Jun‐07
Sep‐07
Dec‐07
Mar‐08
Jun‐08
Sep‐08
Dec‐08
Mar‐09
Jun‐09
Sep‐09
Dec‐09
Mar‐10
Jun‐10
Sep‐10
Dec‐10
Mar‐11
Jun‐11
Sep‐11
%
EAST MIDLANDS
EAST OF ENGLAND
LONDON
NORTH EAST
NORTH WEST
SOUTH CENTRAL
SOUTH EAST COAST
SOUTH WEST
WEST MIDLANDS
YORKSHIRE AND THE HUMBER
ENGLAND
A B CD
E
A Kearney et al. BMJ June 2006B MHRA Advice Oct 2006C MeReC Extra 30,Nov 2007D NPC workshops Feb‐Sept 08E Added into QoF
Prescribing of diclofenac as % total NSAIDs
16
Sodium valproate – pregnancy exposure
Teratogenicity known since first licensing
Evidence accrues - 30-40% exposed children have developmental disorders
Further restrictions and strengthened warnings in product information in 2014
17
18
MHRA Valproate Stakeholders Network
19
20
0
5
10
15
20
25Ja
n - J
un 2
010
Jul -
Dec
201
0
Jan
- Jun
201
1
Jul -
Dec
201
1
Jan
- Jun
201
2
Jul -
Dec
201
2
Jan
- Jun
201
3
Jul -
Dec
201
3
Jan
- Jun
201
4
Jul -
Dec
201
4
Jan
- Jun
201
5
Jul -
Dec
201
5
Jan
- Jun
201
6
Rat
e pe
r 10,
000
wom
en
6 month time period
Epilepsy
Bipolar
Migraine
Missing
Valproate use in women by indication
21
Today’s opportunities
Integration of systems to facilitate risk management
Data sources & methodologies to measure impact
New digitally enabled communication tools
Increasing patient involvement in decisions
Developing partnership working between bodies
22
Integration of adverse event reporting
Monthly webinar meetings to discuss reporting & safety attended by all UK countries
23
Integrating medicines & medical devices vigilance
24
Monitoring impact of safety messaging
25
Yellow Card mobile app
26
Professional bodies
Safety messaging partnerships
Devolved Governments
Clinical Guidelines
27
Moving forwards
Co-ordinated synergistic safety messagingClarity of message and action to be taken
Targeted to right audienceUsing digital tools
Measurable public health protection